Chemours (CC) Tops Q1 EPS by 56c; Offers FY22 EBITDA Guidance

Chemours (NYSE: CC) reported Q1 EPS of $1.46, $0.56 better than the analyst estimate of $0.90. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.56 billion.

FY 2022 Adjusted EBITDA is now expected to be between $1.475 billion and $1.575 billion vs. prior guidance of between $1.3 billion and $1.425 billion. Free Cash Flow is expected to be greater than $550 million vs. prior guidance of greater than $500 million.

For earnings history and earnings-related data on Chemours (CC) click here.

You May Also Be Interested In

• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
• THE CHEMOURS COMPANY (NYSE: CC) DEADLINE ALERT: Bernstein Liebhard LLP Reminds The Chemours Company Investors of Upcoming Deadline
• Spotify (SPOT) jumps 10% as Q1 revenue, gross margins beat Street's estimates